• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Cath Lab Digest

  • Follow us on
  • Home
  • About Us
    • Privacy Policy/Copyright
    • About VDM
    • Editorial Board
    • Contact
  • Issues
    • Current Issue
    • Issue Archives
  • Multimedia
  • Editor's Update
  • Advertise
  • Reprints
  • Authors & Reviewers
    • Author Instructions
    • Submission Portal
    • Reviewers

Search

Sentara Cardiovascular Research Institute Investigates System Designed as Early Warning for Heart Failure Patients

Researchers at Sentara Cardiovascular Research Institute are among top enrollers at 69 leading heart centers in the U.S. involved in a clinical trial designed to investigate a new device to evaluate the safety and efficacy of a physician-directed patient self management system.

The purpose is to determine if an implantable device, smaller than a smart phone, can effectively monitor the pressure in the left atrium of the heart, and manage the patient's medications to reduce episodes of heart failure.

Clinicians commonly use the symptoms of heart failure such as fatigue or shortness of breath to determine a heart failure patient's status and need for treatment. Left atrial pressure is considered an excellent indicator of status, providing the most objective measure. Changes in left atrial pressure occur before fluid retention and worsening of heart failure symptoms.

In this research study, the device is implanted just under the skin in the chest with wires connected to the heart in half of the study patients. This device records left atrial pressure, and a hand-held monitor collects that information, transmits the information to doctors and nurses at the study center over regular phone lines, and directs patients to take medicines or make lifestyle changes as needed. The study is designed to ask patients to increase heart failure medicines to relieve symptoms before they occur.

About LAPTOP-HF
The Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy (LAPTOP-HF) is a randomized, controlled study sponsored by medical device company St. Jude Medical. For more information about the study and eligibility, visit www.clinicaltrials.gov . The study identifier is NCT01121107.

About Sentara. Sentara Healthcare is one of the nation's leading not-for-profit health systems, acknowledged as a leader in patient safety and quality innovation. For more information about Sentara or Sentara Cardiovascular Research Institute, visit www.sentara.com.

Bookmark/Search this post with
  • Digg
  • LinkedIn
  • Reddit
  • Facebook Like
  • Google Plus One
  • Linkedin Share Button
  • Tweet Widget
image description image description


				
  • Advertise your Job Here
    For information on posting classified ads, please contact:
    Kimberly Sutkowski, Classified Sales Representative
    (800) 237-7285, ext. 205

Vascular Access: The VDM Clinician Blog

Anticoagulant Treatment of DVT and Preventing DVT-PE Made Easier

Frank J Criado MD FACS FSVM

Retrograde Crossing: When the Front Door Is Locked, Look for Another Way In!

Ajay U. Mhatre MD

Collecting More Data for Vascular Patients

Lawrence A. Garcia MD

A Road Less Traveled: Access in the Right Brachial Artery

Ajay U. Mhatre MD

Endovascular Options for Complex Abdominal Aortic Aneurysms

Robert S. Dieter MD RVT and Aravinda Nanjundappa MD RVT
more »

Vascular Newswire

  • Elixir Medical Receives CE Mark Approval for the Fully Bioresorbable DESolve Novolimus Eluting Coronary Scaffold System
    Wed, 05/15/13 - 10:12am
  • Reverse Medical Corporation Announces CE Mark and Initial Clinical Experience with the MVP Micro Vascular Plug for Peripheral Embolization
    Wed, 05/15/13 - 8:55am
  • St. Jude Medical Announces First Patient Enrollment in EnligHTN III Renal Denervation Study of Next-Generation EnligHTN System
    Wed, 05/15/13 - 8:52am
  • Decades of Improving Cholesterol Levels Abruptly Ended in 2008, PLOS ONE Study Finds
    Tue, 05/14/13 - 10:02am
more »

Clinical Events Calendar

  • EuroPCR 2013
    Tue, 05/21/2013 - Fri, 05/24/2013
    Paris, France
  • European Society for Vascular Surgery European Vascular Trauma Workshop
    Mon, 05/27/2013 - Tue, 05/28/2013
    Sweden
  • Society for Vascular Surgery Vascular Annual Meeting 2013 (SVS)
    Thu, 05/30/2013 - Sat, 06/01/2013
    San Francisco, CA, United States
more »

Poll

Drug-eluting balloons will have a major role in lower-extremity revascularization in the future.:
REVIEW OUR OTHER Cardiology BRANDS

Our other resources for healthcare professionals.

HMP Communications © 2013 HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. ©2013 HMP Communications